Next Article in Journal
Replicative Stress and the FHIT Gene: Roles in Tumor Suppression, Genome Stability and Prevention of Carcinogenesis
Previous Article in Journal
Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?
Previous Article in Special Issue
Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?
Article Menu

Export Article

Open AccessConcept Paper
Cancers 2014, 6(2), 1195-1207; doi:10.3390/cancers6021195

Circulating Tumor Cells: What Is in It for the Patient? A Vision towards the Future

1
Fellow, Precision and Decentralized Diagnostics, Philips Research, Eindhoven 5656 AE, The Netherlands
2
Chair Microsystems, Eindhoven University of Technology, Postbox 513, Eindhoven 5600 MB, The Netherlands
*
Author to whom correspondence should be addressed.
Received: 13 March 2014 / Revised: 22 April 2014 / Accepted: 22 May 2014 / Published: 28 May 2014
(This article belongs to the Special Issue Circulating Tumor Cells in Cancers)
View Full-Text   |   Download PDF [133 KB, uploaded 28 May 2014]

Abstract

Knowledge on cellular signal transduction pathways as drivers of cancer growth and metastasis has fuelled development of “targeted therapy” which “targets” aberrant oncogenic signal transduction pathways. These drugs require nearly invariably companion diagnostic tests to identify the tumor-driving pathway and the cause of the abnormal pathway activity in a tumor sample, both for therapy response prediction as well as for monitoring of therapy response and emerging secondary drug resistance. Obtaining sufficient tumor material for this analysis in the metastatic setting is a challenge, and circulating tumor cells (CTCs) may provide an attractive alternative to biopsy on the premise that they can be captured from blood and the companion diagnostic test results are correctly interpreted. We discuss novel companion diagnostic directions, including the challenges, to identify the tumor driving pathway in CTCs, which in combination with a digital pathology platform and algorithms to quantitatively interpret complex CTC diagnostic results may enable optimized therapy response prediction and monitoring. In contrast to CTC-based companion diagnostics, CTC enumeration is envisioned to be largely replaced by cell free tumor DNA measurements in blood for therapy response and recurrence monitoring. The recent emergence of novel in vitro human model systems in the form of cancer-on-a-chip may enable elucidation of some of the so far elusive characteristics of CTCs, and is expected to contribute to more efficient CTC capture and CTC-based diagnostics. View Full-Text
Keywords: cancer; metastasis; circulating tumor cell; CTC; digital pathology; companion diagnostics; cell-free DNA; organ-on-chip; computational pathway model cancer; metastasis; circulating tumor cell; CTC; digital pathology; companion diagnostics; cell-free DNA; organ-on-chip; computational pathway model
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

van de Stolpe, A.; den Toonder, J.M.J. Circulating Tumor Cells: What Is in It for the Patient? A Vision towards the Future. Cancers 2014, 6, 1195-1207.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top